SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-013145
Filing Date
2022-05-13
Accepted
2022-05-13 06:05:27
Documents
13
Period of Report
2022-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38102
2 ex99-1.htm EX-99.1 71879
  Complete submission text file 0001493152-22-013145.txt   293000

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qlgn-20220513.xsd EX-101.SCH 3042
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qlgn-20220513_lab.xml EX-101.LAB 34476
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qlgn-20220513_pre.xml EX-101.PRE 22601
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3499
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

IRS No.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 22920096
SIC: 2834 Pharmaceutical Preparations